MiR-1293 affects the biological behavior of breast cancer by targeting LAMB3-mediated PI3K-AKT pathway and multimodal ultrasound imaging of the tumor

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044425

Enrollment

Unknown

Registered

2021-03-18

Start date

2021-03-12

Completion date

Unknown

Last updated

2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

case group:There is no intervention other than the conventional diagnosis and treatment.

Eligibility

Sex/Gender

Female

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Multimodal ultrasonography was performed 2 weeks before surgery; 2. Ultrasound showed that the maximum diameter of solid breast lesions was less than 3.50cm; 3. All patients participating in this study gave informed consent and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Any preoperative antitumor therapy; 2. Patients had undergone a biopsy, surgery, or other special treatment before ultrasound examination.

Design outcomes

Primary

Measure	Time frame
Multimodal ultrasonography of breast masses; expression levels of miR-1293 and Lamb3 in breast tissues;	—

Countries

China

Contacts

Public ContactWeidong Ren

Shengjing Hospital of China Medical University

renwdcmu@163.com+86 24-96615-74194

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026